These results provided evidence that the synergistic inhibition effects observed with the combined therapy of RC48 and dabrafenib can be partially attributed to the induction of PARP and MCL-1-dependent apoptosis, and inhibition of migration and invasion in BRAF-mutant melanoma cells in vitro. Here, MCL1 is linked to melanoma.